Fasiglifam (TAK-875) is a GPR40 agonist which was developed for the treatment of type 2 diabetes. However, during Phase III clinical trials, it was withdrawn due to adverse liver effects.
In this poster, we focus on:
- deciphering the mechanism of hepatotoxicity of fasiglifam (TAK-875)
- understanding the impact of plasma protein binding and mitochondrial effects by fasiglifam using the Seahorse flux analyser platform
Read our poster to learn more about our research!